^
    Back
    Association details:
    Biomarker:NCOR1-LYN fusion
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Front Oncol
    Title:

    Rapid Molecular Response to Dasatinib in a Pediatric Relapsed Acute Lymphoblastic Leukemia With NCOR1-LYN Fusion

    Excerpt:
    A 6-year-old boy with relapsed B-ALL had no response to reinduction chemotherapy. He was then treated with the ABL1 tyrosine kinase inhibitor dasatinib and achieved complete remission within 2 weeks….His bone marrow karyotype showed a balanced translocation between chromosomes 8 and 17, leading to a NCOR1-LYN fusion gene confirmed with sequencing.
    DOI:
    10.3389/fonc.2020.00359
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2018
    Title:

    Leukemic Cell Expressing a Novel Kinase Fusion Protein NCOR1-LYN Exhibits High Sensitivity to Dasatinib and Rapamycin

    Published date:
    11/01/2018
    Excerpt:
    Cytotoxic assay revealed that 1nM of dasatinib suppressed the proliferation of Ba/F3 cells expressing NCOR1-LYN completely (p<0.01), although imatinib didn't show any effect....However, dasatinib didn't show any effect on Ba/F3 cells not expressing NCOR1-LYN.
    DOI:
    10.1182/blood-2018-99-111612